During the past decade, Ordinace pro choroby srdce a cev conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Ordinace pro choroby srdce a cev" are "Severe Hypertriglyceridemia" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Coronary Heart Disease (CHD)" (1 trials). Many other conditions were trialed in "Ordinace pro choroby srdce a cev" in a lesser frequency.

Most popular intervention types in "Ordinace pro choroby srdce a cev" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fenofibrate" (2 trials), "K-877" (2 trials), "Placebo (for K-877)" (2 trials), "Evolocumab" (1 trials) and "Lp(a) Screening" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ordinace pro choroby srdce a cev" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Ordinace pro choroby srdce a cev". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Ordinace pro choroby srdce a cev, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ordinace pro choroby srdce a cev, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".